原发性硬化性胆管炎患者优势狭窄:支架不优于球囊扩张
因无效及治疗相关严重不良事件(SAE)差异,研究提前终止。两组24个月累积无复发通畅率无显著差异,支架组治疗相关SAE显著更多。
要点
- 两组24个月累积无复发通畅率无显著差异(支架组0.34 vs 球囊扩张组0.30,P=1.0)。
- 支架组治疗相关SAE发生率为45%(15例),球囊扩张组为6.7%(2例),OR 11.7(95%CI 2.4-57.2),P=.001。
- 作者结论:球囊扩张应作为PSC优势狭窄的首选初始治疗。
核心结论
- 在PSC伴优势狭窄患者中,短期支架不优于球囊扩张,且与显著更高的治疗相关SAE相关。
- 作者结论:球囊扩张应作为PSC优势狭窄的初始治疗首选。
- 作者认为这一结论对乳头完整的患者可能尤其相关。
研究设计与样本
- 前瞻性、开放标签、多中心随机试验,在欧洲9个三级中心开展,时间为2011年7月至2016年4月。
- 纳入接受治疗性内镜逆行胰胆管造影(ERCP)的非终末期PSC患者,发现优势狭窄后随机分组。
- 球囊扩张组n=31,短期支架组n=34(支架置入最长2周),随访24个月。
- 主要终点为原优势狭窄的累积无复发通畅率。
- 研究因无效及组间治疗相关SAE差异,在计划的中期分析后终止招募。
主要发现
- 24个月累积无复发通畅率:支架组0.34 vs 球囊扩张组0.30,差异无统计学显著(P=1.0)。
- 两组多数患者术后3个月症状减轻。
- 治疗相关SAE共17例:ERCP后胰腺炎9例,细菌性胆管炎4例。
关键数值与推荐
- 治疗相关SAE:支架组15例(45%)vs 球囊扩张组2例(6.7%),OR 11.7(95%CI 2.4-57.2),P=.001。
- 24个月累积无复发通畅率:支架组0.34 vs 球囊扩张组0.30,P=1.0。
- 支架置入最长时间为2周。
临床怎么用
- 作者结论:球囊扩张应作为PSC优势狭窄的初始治疗首选。
- 作者认为上述结论对乳头完整的患者可能尤其相关。
局限性
- 研究因无效及组间治疗相关SAE差异,在计划的中期分析后提前终止招募。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Dominant strictures occur in approximately 50% of patients with primary sclerosing cholangitis (PSC). Short-term stents have been reported to produce longer resolution of dominant strictures than single-balloon dilatation. We performed a prospective study to compare the efficacy and safety of balloon dilatation vs short-term stents in patients with non-end-stage PSC. METHODS: We performed an open-label trial of patients with PSC undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) at 9 tertiary-care centers in Europe, from July 2011 through April 2016. Patients found to have a dominant stricture during ERCP were randomly assigned to groups that underwent balloon dilatation (n = 31) or stent placement for a maximum of 2 weeks (n = 34); patients were followed for 24 months. The primary outcome was the cumulative recurrence-free patency of the primary dominant strictures. RESULTS: Study recruitment was terminated after a planned interim analysis because of futility and differences in treatment-related serious adverse events (SAEs) between groups. The cumulative recurrence-free rate did not differ significantly between groups (0.34 for the stent group and 0.30 for the balloon dilatation group at 24 months; P = 1.0). Most patients in both groups had reductions in symptoms at 3 months after the procedure. There were 17 treatment-related SAEs: post-ERCP pancreatitis in 9 patients and bacterial cholangitis in 4 patients. SAEs occurred in 15 patients in the stent group (45%) and in only 2 patients in the balloon dilatation group (6.7%) (odds ratio, 11.7; 95% confidence interval, 2.4-57.2; P = .001). CONCLUSIONS: In a multicenter randomized trial of patients with PSC and a dominant stricture, short-term stents were not superior to balloon dilatation and were associated with a significantly higher occurrence of treatment-related SAEs. Balloon dilatation should be the initial treatment of choice for dominant strictures in patients with PSC. This may be particularly relevant to patients with an intact papilla. ClinicalTrials.gov no. NCT01398917.
引用
- Ponsioen CY, Arnelo U, Bergquist A, et al. No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology. 2018. PMID: 29803836. doi:10.1053/j.gastro.2018.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。